CHESTER, N.J., June 12, 2017 (GLOBE NEWSWIRE) -- Hillstream BioPharma Inc. (Hillstream), a biopharmaceutical company focused on developing targeted, safer and more effective cancer therapeutics, will present at the 2017 Marcum MicroCap Conference on June 16 at the Grand Hyatt in New York City. Randy Milby, Chief Executive Officer, will present an update on the company and answer questions at 11:00 am ET.
Hillstream BioPharma Inc. is dedicated to developing cancer therapeutics with greater safety and efficacy to help patients with high unmet medical needs. Hillstream’s lead drug, HBP-407, is a novel proprietary formulation of bortezomib, with an improved side effect profile with the potential for reduced peripheral neuropathy, activity against bortezomib-resistant multiple myeloma and a highly targeted effect with the potential for an increased dose to expand the first approved proteasome inhibitor into solid tumors.
Randy Milby, Hillstream’s CEO, said, “Side effects, such as peripheral neuropathy, and drug resistance are two serious problems in cancer patient care. We believe HBP-407 can offer a safer, more effective targeted therapeutic in an orphan population with a high unmet need.”
The Marcum MicroCap Conference (www.marcummicrocap.com) is a nationally recognized forum for publicly traded companies with less than $500 million in market capitalization to network with fund managers and high net worth investors who focus on small cap equities. More than 2000 investors and other participants from every segment of the microcap marketplace attend each year, including venture and lower middle-market private equity investors, institutional investors, directors, investment bankers, and buy- and sell-side analysts, as well as senior executive teams from presenting companies and service providers to the microcap marketplace.
The conference is presented by Marcum LLP, a top national accounting and advisory firm registered with the Public Company Accounting Oversight Board (PCAOB). Marcum's Assurance Division provides the most up-to-date service and guidance on SEC accounting and reporting issues. For more information, visit www.marcumllp.com.
About Hillstream BioPharma Inc.
Hillstream BioPharma Inc. (Hillstream) is a biopharmaceutical company focused on developing cancer therapeutics with greater safety and efficacy to help patients with high unmet medical needs. Hillstream’s lead drug, HBP-407, is a novel proprietary formulation of bortezomib, with an improved side effect profile with the potential for reduced peripheral neuropathy, activity against bortezomib-resistant multiple myeloma and a highly targeted effect with the potential for increased dose to expand the first approved proteasome inhibitor into solid tumors. Hillstream will initially utilize the faster and more de-risked FDA’s 505(b)(2) NDA regulatory pathway for approval of HBP-407. Our goal is to develop pharmaceutical products which play an important role in helping patients lead longer and healthier lives. Please also see www.hillstreambio.com.